


# Computational biomechanics at Zimmer Biomet

**Philippe Favre**

Research Associate Director  
Computational Biomechanics



**ZIMMER BIOMET**  
Moving You Forward.™



# Agenda

**Few words about Zimmer Biomet and me**

**The environment for medical devices**

**Classic use of modeling in the medical device industry**

- Finite element analyses
- Anatomical analyses

**Emerging applications of modeling**


- In silico clinical trials



# Zimmer Biomet

- 17,000 Team Members, globally
- In Switzerland: EMEA headquarter in Zug, production facility in Winterthur
- Fortune 500 company, 2024 net sales of \$7.6 billion

Joint Replacement Market Share by Company



# Musculoskeletal Product and Services Portfolio

#1	Knee Arthroplasty	
#1	Hip Arthroplasty	
#5	Shoulder, Elbow and Wrist Arthroplasty	
	Craniomaxillofacial	
	Thoracic	
	Smart Implants	
	Trauma	
	Foot and Ankle	
	Sports Medicine	



Allograft service

Bone Healing

Early Intervention & Biologics

Surgical Products

Oncology & Specialized Implant Solutions

Bone Cements & Accessories

Mixed Reality

Robotics & Intelligent Instruments

Care Management & Patient Engagement

Predictive Analytics & Data Insights



# Musculoskeletal Product and Services Portfolio

**Knee Arthroplasty**



**Hip Arthroplasty**



**Shoulder, Elbow and Wrist Arthroplasty**



**Craniomaxillofacial**



**Thoracic**



**Smart Implants**



**Trauma**



**Foot and Ankle**



**Sports Medicine**



**Allograft service**



**Bone Healing**



**Early Intervention & Biologics**



**Surgical Products**



**Oncology & Specialized Implant Solutions**



**Bone Cements & Accessories**



**Mixed Reality**



**Robotics & Intelligent Instruments**



**Care Management & Patient Engagement**



**Predictive Analytics & Data Insights**




# Few words about me



Mechanical  
engineering



Biomechanics



PhD  
Group leader  
Clinical Biomech



Research

Comput Biomech manager

1998

2003

2008

2011

2017

Today




# Environment in the medtech industry

# Introducing a new medical device to market

Ensure safety and effectiveness of **product that will be implanted in people**

→ Important consequences if we make the wrong decisions

→ Highly regulated industry



# Risk analysis

What could go wrong?



Analysis  
Tests  
Optimization




Mitigate the  
causes of  
failure




# Biomechanical risks

What could go wrong?



# Model input



VS



Subject created by man, we understand the complexity

Subject created by nature, we try to understand as best we can (ethically)



# Sources of uncertainties

- Anatomy
- Bone quality
- In-vivo loading
- Surgery etc.





# Sources of uncertainties as input




- Anatomy




- Bone quality



- In-vivo loading



- Surgery etc.



# And how we deal with uncertainties

Worst case testing:

*If that passes, it always will*




# And how we deal with uncertainties

Worst case testing:

*If that passes, it always will*


Standards (ISO, ASTM)

ASTM-F2996-20. Standard Practice for Finite Element Analysis (FEA) of Non-Modular Metallic Orthopaedic Hip Femoral Stems, 2020.



ASTM-F3161-16. Standard Test Method for Finite Element Analysis (FEA) of Metallic Orthopaedic Total Knee Femoral Components under Closing Conditions, 2016.

ASTM-F-3334-19. Standard Practice for Finite Element Analysis (FEA) of Metallic Orthopaedic Total Knee Tibial Components, 2019.



# And how we deal with uncertainties

Worst case testing:

*If that passes, it always will*

Standards (ISO, ASTM)

Compare with successful implants (equivalency to predicate)

Final assessment comes only ~10 years after implantation!

New device



?




≤

Existing device with  
long and good clinical  
results

# New product development support

# Establish product safety and efficacy



The classic use of modeling at Zimmer Biomet

# Typical risks that we investigate



## Clinical

Implant fracture  
Aseptic loosening  
Implant subsidence  
Bony atrophy/hypertrophy  
Intra/post OP bone fracture  
Impingement/dislocation

## In silico

Implant fatigue stress  
Micromotion and interface strain  
Permanent displacement  
Change in bone stress  
Bone ultimate/fatigue stress  
Range of motion

Adverse Event Report Form II

Subject ID: Date of Surgery: Investigator ID: Operative Site: Form Completion Date:

1. Adverse Event Code (see descriptions below):

2. Details of Event:

3. Side: Right Left Both

4. Date of Event: \_\_\_\_\_

5. Type of Event: Trauma Aseptic Malfunction

6. Severity: Mild Moderate Severe


7. Is this event related to a Zimmer device and alleged a Device Deficiency? Yes No

8. Details of Treatment:

9. Disposition: Revised Date: Treated: Pending: Risk Assessment Date: Revision Date: Death Date:

10. Date Reported to Your Medical Committee: The Required Police Report: Date of Police Report:


11. 12 Aug 2014 Ver. II



# Worst-case identification

FEA - Finite element analysis

*Significant time and financial gain*





> 100 FEA simulations  
of combinations

1 physical test  
of worst-case







# Design optimization using statistical methods



*Significant time and financial gain*

# Enrich physical testing





**Combined approach to get a better representation of primary stability**


- Full micromotion distribution
- All micromotion components
- Realistic loading conditions

*Impossible to do without modeling*



# MR interaction



# Anatomical studies - virtual surgery



Database of  
bone models



3D CAD models of  
implants




# Support new design


Persona tibial baseplate

*Impractical to do without modeling!*


Generate design inputs



Fit quality of the designs



Support claims



## The personalized design

Tibial bone coverage

**92%**

with proper rotation<sup>1</sup>

Persona Femur is able to match

**97%**


each patient's native A/P dimension<sup>2</sup>

Ideal tibial rotation and alignment

**81.4%**

<sup>1</sup>in vivo<sup>3</sup>

# Range of motion analysis



# Patient-Matched Implants

*Impractical to do without modeling!*


Shoulder




Elbow




Wrist




Hip



Knee




# Model validation




# In silico clinical trials

## ISCT


# Establish product safety and efficacy




# Concept of in silico clinical trials (ISCT)



# Technical approach



# Technical approach for virtual population




45 unique anatomies



Category	Mean	SD	Min	Max
Height [m]	1.70	0.1	1.47	1.93
Weight [kg]	77.3	26.2	36.0	172.0
BMI	26.9	9.4	12.5	65.2

# Technical approach for virtual population




Include surgical variability

→ Total of n=521 unique surgical interventions

45 unique anatomies




Category	Mean	SD	Min	Max
Height [m]	1.70	0.1	1.47	1.93
Weight [kg]	77.3	26.2	36.0	172.0
BMI	26.9	9.4	12.5	65.2



(PMCF: n=47 in TSA, n= 58 in hemi)

# Technical approach for virtual population




45 unique anatomies



Category	Mean	SD	Min	Max
Height [m]	1.70	0.1	1.47	1.93
Weight [kg]	77.3	26.2	36.0	172.0
BMI	26.9	9.4	12.5	65.2

Include surgical variability  
→ Total of n=521 unique surgical interventions



(PMCF: n=47 in TSA, n= 58 in hemi)

3000 solved models



3 load cases



Humeral  
loosening


Stress  
shielding

# Model validation strategy



# ISCT model validation<sup>1</sup>

Computer Methods and Programs in Biomedicine 242 (2023) 107813



Contents lists available at ScienceDirect

Computer Methods and Programs in Biomedicine

journal homepage: [www.elsevier.com/locate/cmpb](http://www.elsevier.com/locate/cmpb)



## A risk and credibility framework for *in silico* clinical trials of medical devices

Jeffrey E. Bischoff <sup>a,\*</sup>, Mehul A. Dharia <sup>a</sup>, Philippe Favre <sup>b</sup>

<sup>a</sup> Zimmer Biomet, 1800 West Center Street, Warsaw, IN, 46580, USA

<sup>b</sup> Zimmer Biomet, Zählerweg 4, 6300 Zug, Switzerland



## Benchtop comparator:



- Ensure physics are modeled correctly
- Best addressed with tight control over test conditions

## Clinical comparator:

- Ensure aspect of clinical performance, including survivorship, can be predicted appropriately
- Reproduce clinically significant differentiation in outcomes b/w different designs, variants, sizes, etc

# Clinical validation – Stress shielding

## Comparator




Nagels et al., JSES 2003

Statistically significant increased proximal lateral humeral cortical thinning for greater relative stem size patients (N=70, Biomodular stems)



## Model

N=35 bones  
Biomodular stem



**Sensitivity**  
Mesh size  
Stem alignment  
Stem size  
Loading  
Material properties

## Comparison



N=188

Change in strain  
energy density  
→ Bone resorption

Statistically significant increased proximal lateral humeral stress-shielding for greater relative stem size patients

# Regulatory uncertainty

## Risk of rejection by the regulator reduced by:

- Following guidelines for clinical studies and computational modelling

[ISO 14155. Clinical investigation of medical devices for human subjects — Good clinical practice, 2011.]

[Guidance for Industry and Food and Drug Administration Staff. Reporting of Computational Modeling Studies in Medical Device Submissions, 2016.]

39



- Open and regular communication with the regulator
- Publish the approach

# Conclusions

- Computer modeling is heavily leveraged at ZB (but it may not be representative of the orthopedic industry)
- Worst-case identification for physical testing is the standard, accepted use
- Allows us to have better implants, while having shorter and more efficient development and testing phases
- V&V work should not be underestimated, but model credibility is priceless
- Further standardization in emerging applications (ISCT) is greatly needed

